7:50 am Breakfast & Registration

An Overview of the Current Standpoint of Neuroimmunology Therapeutic Development

8:50 am Chair’s Opening Remarks

  • Richard Wyse Director of R&D, The Cure Parkinson’s Trust

Biomarker Combinations to Stratify & Monitor Clinical Effect

9:00 am Opening Panel Discussion: What’s New in Neuroimmunology Drug Development?

  • Stanley Appel Co-Director, Houston Methodist Neurological Institute; Advisory Board Chair COYA Therapeutics
  • Jesse Cedarbaum Acting Chief Medical Officer, ImmunoBrain Checkpoint
  • Marianthi Papakosta Head of In Vitro Neuroinflammation Pharmacology, Cell Protection Unit & Neuroscience, Takeda Pharmaceuticals
  • Malu Tansey Professor of Neuroscience & Neurology; Co-Director, University of Florida College of Medicine; Centre for Translational Research in Neurodegenerative Disease

Synopsis

  • What are the new biomarkers and targets within neuroimmunology?
  • Innovation in neuropsychiatric drug development
  • Updates on the role of cells beyond microglia in neuroinflammation

9:30 am Using Digital Biomarkers to Apply a Stratified Approach to Neuroinflammation

Synopsis

  • Applying digital biomarkers, in combination with standard inflammatory markers, to aid identification of people at high risk for neuroinflammation
  • Using prophylactic small molecule approach for neuroinflammation to analyze neuroinflammatory outcomes in patients with post-operative cognitive decline in
  • Referencing the outcomes of the clinical trials conducted by Monument Tx to outline the above

10:00 am Structured Networking

Synopsis

We are excited to return to in person meetings, allowing you to connect with peers face-to-face once again. Join this structured networking session to dissect the latest developments in neuroimmunology drug development, and brainstorm solutions to drug discovery and translational bottlenecks with industry colleagues.

10:45 am Morning Break & Networking

Examining Case Studies of Biomarker Application Across Parkinson’s, Alzheimer’s & FTD

11:15 am Inflammation Biomarkers for Parkinson’s Disease & Fox Foundation Resources

  • Andrew Koemeter-Cox Associate Director, The Michael J Fox Foundation for Parkinson’s Disease

Synopsis

  • Summarizing the Michael J Fox Foundation’s current strategy around inflammation biomarkers and funding in the space
  • Covering Tools, Biospecimens, Funding, and other resources available for researchers through the Michael J Fox Foundation

11:45 am Narrowing the Gap to Diagnose Alzheimer’s Disease Through Biomarkers

  • Alejandro Rangel Applied Neurosciences Department Head, Mexican Council of Neuroscience

Synopsis

  • Analyzing several biomarkers to understand their use for neuroinflammation in neurodegenerative diseases
  • Using CSF biomarkers to narrow the gap to diagnostic tests for Alzheimer’s disease
  • Referencing to current human trials of CSF and blood biomarkers to compare the effectivity of blood versus CSF-based biomakers

12:15 pm Utilizing Inflammatory Biomarkers to Assess the Activity of a Novel Therapeutic in Frontotemporal Dementia Patients with Granulin Mutation

  • Julie Huang Senior Scientist, Biomarker Sciences, Alector

Synopsis

  • Examining biomarkers specifically for frontotemporal dementia, a rapidly progressive form of dementia, to address the gap in therapeutic development for neurodevelopmental disease, as there are currently none approved for this condition
  • Leveraging biomarkers to evaluate hallmarks of frontotemporal dementia pathophysiology to aid drug development
  • Implementing a biomarker strategy in a clinical study to assess treatment impact in frontotemporal patients with a granulin mutation

12:45 pm Lunch & Networking

Rationalizing & Evaluating Preclinical Models Recapitulating the Neuroimmune System for More Robust Translational Drug Development

1:45 pm Using Preclinical Models to Inform Clinical Trial Design Targeting Chronic Inflammation in Neurodegenerative Disease

  • Malu Tansey Professor of Neuroscience & Neurology; Co-Director, University of Florida College of Medicine; Centre for Translational Research in Neurodegenerative Disease

Synopsis

  • Discussing the rationale for the use of animal models to inform clinical trials, with a lens on neuroinflammation
  • Referencing evidence from Parkinson’s and Alzheimer’s disease to compare models used to analyze neuroinflammation in different neurodegenerative disorders
  • Understanding downfalls in current clinical trial designs for neuroinflammation to improve future generations of trials

2:15 pm Translational Models of Neuroinflammation: An Update from Ulysses Neuroscience on Depression, Rare Diseases & Parkinson’s Disease

Synopsis

  • The interferon-alpha back translational model of depression: Where do we stand after two years of studies?
  • Effects of interferon-alpha on synaptic markers
  • Parkinson Disease: A brief overview on our collaboration with Atuka (animal models) and the Michael J Fox Foundation (iPSCs and brain organoids)

2:30 pm Analyzing In Vitro Models of Microglia in Relation to Inflammasomes

  • Marianthi Papakosta Head of In Vitro Neuroinflammation Pharmacology, Cell Protection Unit & Neuroscience, Takeda Pharmaceuticals

Synopsis

  • Studying the use of in vitro models of microglia to understand inflammation in neurodegenerative and neurodegenerative diseases
  • Translating the results of in vitro models of neuroinflammation to unpick disease standpoint and progression
  • Establishing neuroinflammatory responses from in vitro animal and cellular models to aid patient stratification for inhibitor of the innate immune system

3:00 pm Immunomodulation of Tau Pathology in Organotypic Brain Slice Cultures

  • Brenda Moore Research Assistant Professor, University of Florida

Synopsis

  • Looking at an organotypic brain slice culture rAAV-based model of tauopathy to study the overexpression of immunomodulators in neurodegenerative diseases
  • Using fluorescently tagged markers for live imaging to allow identification of neuroinflammation changes in neurodegenerative disease patients
  • Focusing on the overexpression of specific chemokines and cytokines to analyze the immunological factors of different neurodegenerative diseases

3:30 pm Afternoon Break & Networking

Advancing Clinical Progress: A Look into the Successes & Challenges

4:00 pm Therapeutics for Neurodegenerative Disease – Cutting All 3 Legs

Synopsis

  • Understanding why addressing the immunopathology of neurodegenerative disorders will be key to effective treatment to improve future drug development
  • A brief survey of differences between neurodegenerative diseases to highlight the implications of inflammatory differences across diseases
  • Proposals for solutions to issues with current neuroinflammation studies to drive the next generation

4:30 pm Approaching Clinical Trials Targeting the Immune System: Understanding Biomarker Selection & Treatment Responses

Synopsis

  • Analyzing at biomarker selection and treatment responses and what they mean to understand how Inmune Bio approach clinical trials targeting the immune system
  • Challenging how we view the immune system to gain a better appreciation for drug development relating to biomarkers for neuroinflammation
  • Referring to the results of a recent Phase 1 study to provide evidential backing for the above

5:00 pm Suppressing Neuroinflammation: T-REG Cell Therapy of ALS

  • Stanley Appel Co-Director, Houston Methodist Neurological Institute; Advisory Board Chair COYA Therapeutics

Synopsis

  • Analyzing T-regs dysfunctional in neurodegenerative diseases to aid future therapeutic development
  • Understanding how ex vivo expansion restores T-Reg suppressive function to highlight neuroprotective factors that may arise from targeting neuroinflammation
  • Using clinical trial data to highlight how autologous T-reg infusions slow disease progression to thus suggest a potential avenue towards curing neurodegenerative diseases

5:30 pm End of Conference Day One